2017-08-29T17:36:17-05:00 2016-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2016-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW No 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2017-08-29 1 Nicole M Prince CPA P01315245 7038930300 2017-08-29 72.214.41.82 2017-08-29 18:36:09 ED P 8710F3933DCAF8C038AAB14033CD7B10575F5C30 6C9B1A35775087DBDB8A6D25ECA509C7F6C27838 2016 2021-01-29 14:40:06Z X Amy Finan 2175 K Street NW No 400 Washington DC 20037 14799047 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization across the globe. 9 8 58 0 0 0 17896741 14719648 18100 19975 23756 27774 0 31650 17938597 14799047 4057320 3816018 0 0 5001014 4433036 0 19155 437236 9907750 10422006 18966084 18690215 -1027487 -3891168 22290063 17144106 1844378 1661569 20445685 15482537 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 7537325 1779249 Sabin Vaccine Institute Product Development Partnership (Sabin PDP): The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.For the past 16 years, the Sabin Vaccine Institute Product Development Partnership has conducted research to develop new, low-cost vaccines for diseases impacting the world's most neglected and vulnerable populations, including the first and only vaccine candidate for human hookworm to be assessed in clinical trials, and vaccines candidates for intestinal schistosomiasis infection and Chagas disease.The Sabin Vaccine Institute is committed to supporting research to identify innovative solutions that will improve the lives of millions through immunization. With new management and a renewed dedication to improving human health through immunization, Sabin is evaluating opportunities to engage in innovative research and form new partnerships. 1401951 415040 Global Network for Neglected Tropical Diseases: Nearly one in six people suffer from NTDs - bacterial and parasitic diseases that disable people and perpetuate poverty. The Global Network for Neglected Tropical Diseases, an initiative of the Sabin Vaccine Institute, is dedicated to raising the awareness, political will, and funding required to eliminate these diseases as a public health threat to the world's poorest communities. 6983330 1621729 Vaccine Advocacy and Education Program: Despite scientific advances and international support, 1.5 million children still die each year from diseases that could have been prevented by routine immunization. Sabin works with key decision makers and immunization experts at the country and global level to build resilient, sustainable national immunization programs to reach every child.Sabin is an adviser, a convener and a catalyst of systemic change, bringing together researchers, national government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. In order to make informed decisions about vaccine introduction and implementation, countries require high-quality information and evidence. Sabin supports surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. By establishing and sharing best practices, we help countries evaluate and streamline vaccine introduction and scale-up.Sabin drives meaningful, well-informed conversations on emerging and established issues across the field of immunization and provides training and education on the latest in vaccine science and policy to immunization professionals, journalists and vaccine scientists.Sabin connects immunization professionals with the resources they need to overcome barriers to vaccination and improve vaccine uptake and coverage in their countries. Our scientific meetings, trainings and workshops provide professionals with the skills and tools to strengthen their countries' vaccine research capabilities, foster vaccination program resiliency and implement successful immunization campaigns.Sabin works to shape the vaccine conversation by amplifying reliable information on vaccines. We serve as a leading voice on critical issues in global immunization, including vaccine confidence, vaccine safety and global health innovation. We also work to drive more effective, accurate media coverage on vaccines by equipping journalists with the latest information on disease burden and immunization. 15922606 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 21 0 1 58 1 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X X The Organization 2028428610 2175 K Street NW No 400 Washington DC 20037 Axel Hoos Chairman 5.00 X X 0 0 0 Peter Thoren Vice Chairman 1.00 X X 0 0 0 Kenneth Kelley Trustee 1.00 X 0 0 0 Paul Maddon Trustee 1.00 X 0 0 0 Jordan Orange Trustee 1.00 X 0 0 0 Michael Posner Trustee 1.00 X 0 0 0 Regina Rabinovhich Trustee 1.00 X 0 0 0 Gary Rosenthal Trustee 1.00 X 0 0 0 Philip Russell Trustee 1.00 X 0 0 0 Scott Wulfe Trustee 1.00 X 0 0 0 Michael Whitham Trustee 1.00 X 0 0 0 Michael Marine - CEOend April Board Secretary(start May 2016) 40.00 X X 130103 0 3673 Brian Davis COO 40.00 X 226967 0 30790 Jon Andrus Executive Vice President 40.00 X 262747 0 20601 Peter Hotez Ex Officio Trustee, President 10.00 X 70000 0 0 Amy Finan Ex Officio Trustee, CEO 40.00 X 230556 0 7167 Denise Garrett Vice President, Typhoid Programs 40.00 X 190604 0 21850 Ana Carvalho Program Director 40.00 X 181924 0 29094 Neeraj Mistry Program Director 40.00 X 180779 0 9031 Michael McQuestion Program Director 40.00 X 143732 0 20105 Tara Hayward Vice President, Resource Development and Policy 40.00 X 130921 0 19879 1748333 0 162190 13 0 1 0 Boston Consulting Group PO Box 75200 Chicago IL 60675 Strategic planning 631389 Infectious Disease Research Institute 1616 Eastlake Ave East Suite 400 Seattle WA 98102 Adjuvant manufacture, supply and storage 240961 US TreasuryWRAIR 503 Robert Grant Avenue Silver Spring MD 20910 Antigen manufacture 142396 DF Net Research Inc 140 Lakeside Avenue Suite 310 Seattle WA 98122 Clinical trials data management and stat 132824 Centers for Disease Control & Prevention PO Box 15580 Atlanta GA 30333 Pertussis surveillance 108284 5 446629 14273019 3451 14719648 Membership dues 900099 19975 19975 19975 27774 27774 Refunds 900099 31650 31650 31650 14799047 19975 0 59424 X 1942388 1942388 1873630 1873630 982605 739268 167502 75835 2855535 2146886 485131 223518 87887 65649 17632 4606 249821 191616 41854 16351 257188 195193 43250 18745 5272 5272 15330 15330 19155 19155 6878529 6097506 756725 24298 80521 55305 25140 76 124288 68811 52548 2929 66885 36689 26158 4038 534844 15263 519581 689516 638105 15750 35661 1540461 1496365 43670 426 1502 1501 1 268634 252600 16034 115090 40066 75024 Dues/subscriptions 50169 32783 9400 7986 Recruitment 25189 16322 6160 2707 Miscellaneous 21000 7504 13483 13 Books & publications 4776 3884 892 18690215 15922606 2330373 437236 6552660 2388225 9679523 9861579 2713188 1435208 87026 270584 218799 142853 323784 294616 31148 29168 226583 2970153 2717553 37566 72353 22290063 17144106 1630503 1329780 128996 85024 84879 246765 1844378 1661569 X 2148552 1728442 18297133 13754095 20445685 15482537 22290063 17144106 X -3891168 -1071980 X X 0 1 X 1 0 X 25314757 19979693 18983738 17896741 14719648 96894577 25314757 19979693 18983738 17896741 14719648 96894577 51297812 45596765 30674 24246 28526 23756 27774 134976 31650 31650 97061203 57225 0.46980 0.41890 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 784 3479 4263 18666797 18671060 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 2130 2692 5538 4263 14623 250000 250000 250000 250000 1000000 1500000 719 1217 1897 784 4617 323784 294616 29168 0 29168 Deferred rent 12539 Deferred compensation liability 234226 246765 X 15285730 486683 486683 14799047 0 14799047 19176898 486683 486683 18690215 0 18690215 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 East Asia and the Pacific 0 0 Grants to recipients located in region Typhoid study sites, vaccine development 1430713 South Asia 0 0 Grants to recipients located in region Clinical trial site 257294 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region Vaccine advocacy, NTD control advocacy 185622 0 0 0 0 0 0 1873629 0 1873629 East Asia and the Pacific Typhoid study sites 350000 EFT East Asia and the Pacific Typhoid study sites 725000 EFT East Asia and the Pacific Vaccine advocacy to NTD control 75079 EFT South Asia NTD control 60547 EFT South Asia Typhoid study sites 150000 EFT East Asia and the Pacific Typhoid study sites 249981 EFT East Asia and the Pacific NTD control 30653 EFT South Asia Typhoid study sites 40448 EFT Europe (Including Iceland & Greenland) Vaccine and NTD control advocacy 135622 EFT Europe (Including Iceland & Greenland) NTD control 50000 EFT 10 Site principal investigators South Asia 4 6300 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X X 1 Bridge Consulting PBC 2205 South Holly Street Unit 8 Denver CO 80222 Development strategy and outreach 0 0 18000 -18000 18000 -18000 MD NY DC CA FL TX 1 Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 501C3 645970 Vaccine research IDT Biologika 1405 Research Blvd Rockville MD 20850 264435218 417241 Antigen manufacture The George Washington University 2300 I Street NW Washington DC 20147 530196584 501C3 711315 Vaccine clinical trials Helen Keller International 352 Park Avenue South Suite 1200 New York NY 10010 135562162 501C3 28788 NTD control Pan American Health Organization 525 23rd Street NW Washington DC 20037 237072046 39074 NTD control Stanford University PO Box 44253 San Francisco CA 94144 941156365 501C3 100000 Typhoid study sites 5 1 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X 1 0 0 0 0 0 0 0 0 Brian Davis COO 206967 0 20000 0 0 0 8600 0 22190 0 257757 0 0 0 Jon Andrus Executive Vice President 247747 0 15000 0 0 0 10000 0 10601 0 283348 0 0 0 Amy Finan Ex Officio Trustee, CEO 230556 0 0 0 0 0 0 0 7167 0 237723 0 0 0 Denise Garrett Vice President, Typhoid Programs 190604 0 0 0 0 0 7791 0 14059 0 212454 0 0 0 Ana Carvalho Program Director 181924 0 0 0 0 0 7696 0 21398 0 211018 0 0 0 Neeraj Mistry Program Director 76946 0 8000 0 95833 0 2683 0 6348 0 189810 0 0 0 Michael McQuestion Program Director 123065 0 4000 0 16667 0 4667 0 15438 0 163837 0 0 0 Tara Hayward Vice President, Resource Development 130921 0 0 0 0 0 5591 0 14288 0 150800 0 0 0 Part I, Line 4a Mike McQuestion and Neeraj Mistry received severance payments. Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accountanting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management and Board Chair are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Vaccine development program contract expenses: Program service expenses 5,003,913. Management and general expenses 32,897. Fundraising expenses 23,949. Total expenses 5,060,759. Transcription Service: Program service expenses 30,795. Management and general expenses 0. Fundraising expenses 89. Total expenses 30,884. Consultants: Program service expenses 1,062,798. Management and general expenses 723,828. Fundraising expenses 260. Total expenses 1,786,886. Form 990, Part XI, line 9: Write-off of pledge rescission -1,071,980. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.